KITLG and cardiovascular disorder: Moreover, a clinical trial implemented by Wigren et al. (2016) suggested that the SCF decrease complied with the incidence of coronary events, and SCF was considered a therapeutic strategy to treat cardiovascular disease (Wigren et al., 2016).